Literature DB >> 21674360

Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.

Shinya Tominaga-Sato1, Hideki Tsushima2, Koji Ando3, Hidehiro Itonaga1, Yoshitaka Imaizumi4, Daisuke Imanishi4, Masako Iwanaga1, Jun Taguchi1, Takuya Fukushima4, Shinichiro Yoshida3, Tomoko Hata4, Yukiyoshi Moriuchi5, Kazutaka Kuriyama6, Hiroyuki Mano7, Masao Tomonaga8, Yasushi Miyazaki1.   

Abstract

The percentage of myeloperoxidase (MPO)-positive blast cells is a simple and highly significant prognostic factor in AML patients. It has been reported that the high MPO group (MPO-H), in which >50% of blasts are MPO activity positive, is associated with favorable karyotypes, while the low MPO group (≤50% of blasts are MPO activity positive, MPO-L) is associated with adverse karyotypes. The MPO-H group shows better survival even when restricted to patients belonging to the intermediate chromosomal risk group or those with a normal karyotype. It has recently been shown that genotypes defined by the mutational status of NPM1, FLT3, and CEBPA are associated with treatment outcome in patients with cytogenetically normal AML. In this study, we aimed to evaluate the relationship between MPO positivity and gene mutations found in normal karyotypes. Sixty AML patients with normal karyotypes were included in this study. Blast cell MPO positivity was assessed in bone marrow smears stained for MPO. Associated genetic lesions (the NPM1, FLT3-ITD, and CEBPA mutations) were studied using nucleotide sequencing. Thirty-two patients were in the MPO-L group, and 28 patients in the MPO-H group. FLT3-ITD was found in 11 patients (18.3%), NPM1 mutations were found in 19 patients (31.7%), and CEBPA mutations were found in 11 patients (18.3%). In patients with CEBPA mutations, the carrying two simultaneous mutations (CEBPA (double-mut)) was associated with high MPO expression, while the mutant NPM1 without FLT3-ITD genotype was not associated with MPO activity. Both higher MPO expression and the CEBPA (double-mut) genotype appeared to be associated with improved overall survival after intensive chemotherapy. Further studies are required to determine the importance of blast MPO activity as a prognostic factor, especially in CEBPA wild-type patients with a normal karyotype.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674360     DOI: 10.1007/s12185-011-0883-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  28 in total

1.  Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.

Authors:  Nicolas Boissel; Aline Renneville; Valeria Biggio; Nathalie Philippe; Xavier Thomas; Jean-Michel Cayuela; Christine Terre; Isabelle Tigaud; Sylvie Castaigne; Emmanuel Raffoux; Stephane De Botton; Pierre Fenaux; Herve Dombret; Claude Preudhomme
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

2.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Authors:  H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

3.  Expression of the myeloperoxidase gene in AC133 positive leukemia cells relates to the prognosis of acute myeloid leukemia.

Authors:  Jun Taguchi; Yasushi Miyazaki; Chizuko Tsutsumi; Yasushi Sawayama; Koji Ando; Hideki Tsushima; Takuya Fukushima; Tomoko Hata; Shinichiro Yoshida; Kazutaka Kuriyama; Sumihisa Honda; Itsuro Jinnai; Hiroyuki Mano; Masao Tomonaga
Journal:  Leuk Res       Date:  2006-02-02       Impact factor: 3.156

4.  Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.

Authors:  Shigeki Ohtake; Shuichi Miyawaki; Hiroyuki Fujita; Hitoshi Kiyoi; Katsuji Shinagawa; Noriko Usui; Hirokazu Okumura; Koichi Miyamura; Chiaki Nakaseko; Yasushi Miyazaki; Atsushi Fujieda; Tadashi Nagai; Takahisa Yamane; Masafumi Taniwaki; Masatomo Takahashi; Fumiharu Yagasaki; Yukihiko Kimura; Norio Asou; Hisashi Sakamaki; Hiroshi Handa; Sumihisa Honda; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal:  Blood       Date:  2010-08-06       Impact factor: 22.113

5.  Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.

Authors:  Shigeki Ohtake; Shuichi Miyawaki; Hitoshi Kiyoi; Yasushi Miyazaki; Hirokazu Okumura; Shin Matsuda; Tadashi Nagai; Yuji Kishimoto; Masaya Okada; Masatomo Takahashi; Hiroshi Handa; Jin Takeuchi; Shinichi Kageyama; Norio Asou; Fumiharu Yagasaki; Yasuhiro Maeda; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal:  Int J Hematol       Date:  2010-03       Impact factor: 2.490

6.  Expression of myeloperoxidase enhances the chemosensitivity of leukemia cells through the generation of reactive oxygen species and the nitration of protein.

Authors:  Y Sawayama; Y Miyazaki; K Ando; K Horio; C Tsutsumi; D Imanishi; H Tsushima; Y Imaizumi; T Hata; T Fukushima; S Yoshida; Y Onimaru; M Iwanaga; J Taguchi; K Kuriyama; M Tomonaga
Journal:  Leukemia       Date:  2008-02-14       Impact factor: 11.528

7.  Identification of an upstream enhancer containing an AML1 site in the human myeloperoxidase (MPO) gene.

Authors:  G E Austin; W G Zhao; A Regmi; J P Lu; J Braun
Journal:  Leuk Res       Date:  1998-11       Impact factor: 3.156

8.  C/EBP and C-Myb sites are important for the functional activity of the human myeloperoxidase upstream enhancer.

Authors:  Congjun Yao; Zhenyu Qin; Kimberly N Works; Garth E Austin; Andrew N Young
Journal:  Biochem Biophys Res Commun       Date:  2008-04-22       Impact factor: 3.575

9.  Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).

Authors:  Claude Preudhomme; Christophe Sagot; Nicolas Boissel; Jean-Michel Cayuela; Isabelle Tigaud; Stéphane de Botton; Xavier Thomas; Emmanuel Raffoux; Charlotte Lamandin; Sylvie Castaigne; Pierre Fenaux; Hervé Dombret
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

10.  The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor.

Authors:  P F Erickson; M Robinson; G Owens; H A Drabkin
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

View more
  5 in total

1.  Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation of DNA methyltransferase DNMT3B.

Authors:  H Itonaga; D Imanishi; Y-F Wong; S Sato; K Ando; Y Sawayama; D Sasaki; K Tsuruda; H Hasegawa; Y Imaizumi; J Taguchi; H Tsushima; S Yoshida; T Fukushima; T Hata; Y Moriuchi; K Yanagihara; Y Miyazaki
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

2.  Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.

Authors:  Luiza Handschuh; Maciej Kaźmierczak; Marek C Milewski; Michał Góralski; Magdalena Łuczak; Marzena Wojtaszewska; Barbara Uszczyńska-Ratajczak; Krzysztof Lewandowski; Mieczysław Komarnicki; Marek Figlerowicz
Journal:  Int J Oncol       Date:  2017-12-28       Impact factor: 5.650

3.  Bioinformatics Analysis Identifies Key Genes and Pathways in Acute Myeloid Leukemia Associated with DNMT3A Mutation.

Authors:  Shuyi Chen; Yimin Chen; Jielun Lu; Danyun Yuan; Lang He; Huo Tan; Lihua Xu
Journal:  Biomed Res Int       Date:  2020-11-23       Impact factor: 3.411

4.  Prognostic nomogram for previously untreated adult patients with acute myeloid leukemia.

Authors:  Zhuojun Zheng; Xiaodong Li; Yuandong Zhu; Weiying Gu; Xiaobao Xie; Jingting Jiang
Journal:  Oncotarget       Date:  2016-11-01

5.  [Correlation between myeloperoxidase expression and gene alterations and prognosis in acute myeloid leukemia].

Authors:  X Y Dong; Y L Li; L Jiang; C Y Wu; B J Shang; L Zhang; W Cheng; Z M Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-01-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.